Stay Informed on Key Developments

Investor News and Updates

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

301 - 310of 392 News

March 08, 2019

Not intended for U.S. and UK Media

Bayer submits European marketing authorization application for darolutamide

March 05, 2019

Not intended for U.S. and UK Media

Bayer submits darolutamide for marketing authorization in Japan

February 27, 2019

Fiscal 2018:

Bayer increases sales and earnings - leader in agriculture after acquisition

February 27, 2019

Not intended for U.S. and UK Media

Bayer completes rolling submission for darolutamide in U.S.

February 26, 2019

Bayer proposes dividend for 2018 of 2.80 euros per share

February 15, 2019

Not intended for U.S. and UK Media

Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)

February 14, 2019

Not intended for U.S. and UK Media - American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019

Bayer’s darolutamide plus ADT significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

January 08, 2019

New predictive seed placement technology delivers strong results in 2018:

Bayer expands digital innovation pipeline at The Climate Corporation to bring breakthrough digital tools to more farmers

December 20, 2018

Not intended for U.S. and UK Media

Bayer receives approval in China for endometriosis treatment Visanne™

December 18, 2018

Bayer extends credit line and increases volume to 4.5 billion euros

Inform Yourself on Special Topics

Investor News and Updates

Control Weeds, Not Farming

Everything You Need to Know About Glyphosate

Managing Glyphosate Litigation

Managing and Mitigating PCB Litigation Risk